Advertisement
Screener

Definium Therapeutics, Inc. (DFTX) Graph

DFTX Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $48.66M; Operating expenses $75.08M; Income tax (m); Net income -$158.99M.
  • 2026-03-31: Research and development $41.48M; Operating expenses $59.22M; Income tax (m); Net income -$77.10M.
  • 2025-12-31: Research and development $33.52M*; Operating expenses $47.58M*; Income tax (m); Net income -$50.44M*.
  • 2025-09-30: Research and development $30.98M; Operating expenses $45.67M; Income tax (m); Net income -$67.27M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$48.66M$75.08M(m)-$158.99M
2026-03-31$41.48M$59.22M(m)-$77.10M
2025-12-31$33.52M*$47.58M*(m)-$50.44M*
2025-09-30$30.98M$45.67M(m)-$67.27M
2025-06-30$29.81M$40.90M(m)-$42.74M
2025-03-31$23.36M$32.16M(m)-$23.35M
2024-09-30$17.19M$24.79M(m)-$13.68M
2024-06-30$14.64M$24.46M(m)-$5.85M
2024-03-31$11.71M$22.20M(m)-$54.40M
2023-09-30$13.20M$21.62M(m)-$17.92M
2023-06-30$14.78M$29.18M(m)-$29.13M
2023-03-31$12.60M$20.86M(m)-$24.82M
2022-09-30$7.77M$16.98M$0.00-$16.48M
2022-06-30$9.33M$16.94M$0.00-$16.96M
2022-03-31$10.24M$18.50M(m)-$18.45M
2021-09-30$9.02M$17.23M$0.00-$17.20M
2021-06-30$8.07M$45.22M$0.00-$45.25M
2021-03-31$6.81M$13.85M(m)-$13.76M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$90.15M$134.30M(m)-$236.08M
2025-06-30$53.17M$73.06M(m)-$66.09M
2024-06-30$26.35M$46.66M(m)-$60.25M
2023-06-30$27.38M$50.05M(m)-$53.95M
2022-06-30$19.57M$35.45M$0.00-$35.41M
2021-06-30$14.89M$59.07M$0.00-$59.01M

Revenue and expense 7 month

Period endResearch and developmentOperating expensesNet income
2019-12-31$7.55M$10.73M(m)

Revenue and expense 9 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-09-30$84.14M$118.73M(m)-$133.36M
2024-09-30$43.54M$71.45M(m)-$73.94M
2023-09-30$40.58M$71.66M(m)-$71.87M
2022-09-30$27.34M$52.43M$0.00-$51.89M
2021-09-30$23.91M$76.30M$0.00-$76.21M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$117.67M$166.31M$0.00-$183.79M
2024-12-31$65.30M$103.92M(m)-$108.68M
2023-12-31$52.12M$93.87M(m)-$95.73M
2022-12-31$36.17M$66.33M(m)-$56.80M
2021-12-31$34.79M$93.85M-$1.16M-$93.04M
2020-12-31$18.63M$33.03M(m)-$33.94M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cronos Group Inc. (CRON)$1.223B
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
Canopy Growth Corp (CGC)$0.395B
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
Niagen Bioscience, Inc. (NAGE)United States$0.238B15.72
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B